Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Decitabine/Tetrahydrouridine for Relapsed/Refractory Lymphoid Malignancies
NCT02846935Phase 1Completed
- Start
- Apr 2017
- Primary completion
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of decitabine in T-cell lymphoma, aggressive B-cell lymphoma, indolent B-cell lymphoma and 1 more. Primary endpoint: Objective Response Rate at 52 weeks. Started Apr 2017; status: completed.
02
Drugs
decitabine
03
Conditions
T-cell lymphomaaggressive B-cell lymphomaindolent B-cell lymphomanon-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT02846935.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02846935.